BACKGROUND: Coronavirus disease-19 (COVID-19) is associated with significant mortality. The elderly, patients with comorbidities, and solid organ transplant (SOT) recipients are particularly at risk. We observed a low incidence of severe disease in our population and aimed to determine the outcomes of COVID-19 (disease severity/intensive care unit [ICU] admissions/mortality) in SOT recipients. METHODS: All SOT recipients diagnosed with COVID-19 were included. Their demographic and clinical data were recorded from the hospital electronic system. Patients were assigned to 1 of 4 stages of disease severity: stage A = asymptomatic, stage B = mild, stage C = moderate, and stage D = severe. RESULTS: Of the 3052 SOT recipients, 67 were diagnosed with COVID-19. The mean age was 52 years, and 69% were male. There were approximately 25% patients in stage A, 28% in stage B, 34% in stage C, and 12% in stage D. Patients in stages C and D were older than those in stage A (P = 0.04) or stage B (P = 0.03). Lactic dehydrogenase (P < 0.01) and D-dimer (P < 0.01) levels were higher across the stages. Approximately 70% of patients were admitted for a median duration of 9 days and the median follow-up was 35 days. Acute kidney injury occurred in 19% of patients, and 45% required supplementary oxygen. The symptomatic patients were treated with Hydroxychloroquine (83%), Azithromycin (89%), and Tocilizumab (23%). Around 15% of patients were admitted to ICU and 2 patients have died. CONCLUSIONS: Most SOT recipients developed mild to moderate COVID-19 infection; few required ICU admission and 2 patients have died. Remaining patients have recovered and have been discharged from the hospital.
BACKGROUND:Coronavirus disease-19 (COVID-19) is associated with significant mortality. The elderly, patients with comorbidities, and solid organ transplant (SOT) recipients are particularly at risk. We observed a low incidence of severe disease in our population and aimed to determine the outcomes of COVID-19 (disease severity/intensive care unit [ICU] admissions/mortality) in SOT recipients. METHODS: All SOT recipients diagnosed with COVID-19 were included. Their demographic and clinical data were recorded from the hospital electronic system. Patients were assigned to 1 of 4 stages of disease severity: stage A = asymptomatic, stage B = mild, stage C = moderate, and stage D = severe. RESULTS: Of the 3052 SOT recipients, 67 were diagnosed with COVID-19. The mean age was 52 years, and 69% were male. There were approximately 25% patients in stage A, 28% in stage B, 34% in stage C, and 12% in stage D. Patients in stages C and D were older than those in stage A (P = 0.04) or stage B (P = 0.03). Lactic dehydrogenase (P < 0.01) and D-dimer (P < 0.01) levels were higher across the stages. Approximately 70% of patients were admitted for a median duration of 9 days and the median follow-up was 35 days. Acute kidney injury occurred in 19% of patients, and 45% required supplementary oxygen. The symptomatic patients were treated with Hydroxychloroquine (83%), Azithromycin (89%), and Tocilizumab (23%). Around 15% of patients were admitted to ICU and 2 patients have died. CONCLUSIONS: Most SOT recipients developed mild to moderate COVID-19infection; few required ICU admission and 2 patients have died. Remaining patients have recovered and have been discharged from the hospital.
Authors: Raphaël Duivenvoorden; Priya Vart; Marlies Noordzij; Augusto C Soares Dos Santos; Alex B Zulkarnaev; Casper F M Franssen; Dirk Kuypers; Erol Demir; Hormat Rahimzadeh; Julia Kerschbaum; Kitty J Jager; Kultigin Turkmen; Marc H Hemmelder; Marcel Schouten; María Luisa Rodríguez-Ferrero; Marta Crespo; Ron T Gansevoort; Luuk B Hilbrands Journal: Transplantation Date: 2022-04-26 Impact factor: 5.385
Authors: Laura Linares; Frederic Cofan; Fritz Diekmann; Sabina Herrera; María Angeles Marcos; María Angeles Castel; Marta Farrero; Jordi Colmenero; Pablo Ruiz; Gonzalo Crespo; Jaume Llopis; Carolina Garcia-Vidal; Àlex Soriano; Asunción Moreno; Marta Bodro Journal: PLoS One Date: 2021-03-03 Impact factor: 3.240
Authors: Amani H Yamani; Basem M Alraddadi; Reem S Almaghrabi; Afnan A Amer; Fatimah S Mehdawi; Mohammed A Al-Hamzi; Meshari S Aldajani; Majda S Alattas; Aiman M Elsaed Ramadan; Ghassan Y Wali; Abeer N Alshukairi; Abbas Al Mutair Journal: Immun Inflamm Dis Date: 2022-01-14
Authors: Chia Wei Teoh; Marie-Michele Gaudreault-Tremblay; Tom D Blydt-Hansen; Aviva Goldberg; Steven Arora; Janusz Feber; Valerie Langlois; Michelle Ruhl; Veronique Phan; Catherine Morgan; Philip Acott; Lorraine Hamiwka Journal: Can J Kidney Health Dis Date: 2020-11-13
Authors: Fabiana G Marcondes-Braga; Ciro M Murad; Deborah S P Belfort; Rafael C T Dantas; Maria Tereza S S Lira; Carlos A S Aragão; Rinaldo F Siciliano; Sandrigo Mangini; Luis Fernando B C Seguro; Iáscara W Campos; Mônica S Avila; Mariana V O Bello; Fernanda B A Dos Santos; Tânia M V Strabelli; Fabio A Gaiotto; Fernando Bacal Journal: Transplantation Date: 2022-03-01 Impact factor: 4.939